Management of Clozapine-Induced Tachycardia
For persistent clozapine-induced tachycardia with normal ECG and stable vital signs, initiate pharmacological treatment with a beta blocker (atenolol or bisoprolol) or ivabradine. 1
Understanding Clozapine-Induced Tachycardia
Tachycardia is extremely common with clozapine, affecting 68% of patients on this medication. 1 This adverse effect is often transient during initial titration but can persist and requires routine monitoring throughout treatment. 1
Clinical Assessment
Since your patient has:
- Normal ECG
- Other vital signs within normal limits
- No acute distress
The key concern is distinguishing between:
- Benign persistent tachycardia (most likely in your case)
- Early myocarditis (typically occurs in first months after initiation) 1
Important caveat: If this patient is within the first few months of clozapine initiation, maintain heightened vigilance for myocarditis even with a normal ECG, as myocarditis typically presents early in treatment. 1
Management Algorithm
Step 1: Determine Timing
- If during initial titration: The tachycardia may be transient. Consider slowing the titration rate before adding medications. 1
- If persistent beyond titration: Proceed to pharmacological management.
Step 2: Pharmacological Treatment
First-line options (choose one):
- Beta blockers: Atenolol or bisoprolol 1
- Ivabradine: A tonic agent that selectively reduces heart rate 1
Both approaches are endorsed by the most recent 2026 global Delphi consensus guidelines from The Lancet Psychiatry. 1
Step 3: Ongoing Monitoring
According to the 2026 consensus guidelines 1:
- Tachycardia should be on your routine ADR monitoring checklist at every visit
- Annual ECGs should be considered (though not mandated, as consensus was 63% agreement, below the 75% threshold) 1
- Echocardiograms are only indicated if clinical symptoms develop—not routinely recommended 1
Critical Pitfalls to Avoid
Don't dismiss tachycardia as benign without treatment: While common, persistent tachycardia contributes to long-term cardiovascular complications including cardiomyopathy. 1
Don't stop clozapine for isolated tachycardia: The psychiatric benefits typically outweigh this manageable side effect. Treat the tachycardia pharmacologically rather than discontinuing this highly effective antipsychotic.
Don't order routine echocardiograms: The 2026 guidelines explicitly recommend against annual echocardiograms in asymptomatic patients, as cardiomyopathy in clozapine patients is more likely due to comorbidities (obesity, diabetes, tachycardia itself) rather than direct clozapine cardiotoxicity. 1
Monitor for myocarditis if early in treatment: Even with normal ECG and vitals, if fever develops (≥38.5°C/101.3°F) in the first months of treatment, interrupt clozapine and obtain urgent cardiac workup. 2
Practical Implementation
Initiate beta blocker therapy (e.g., atenolol 25-50 mg daily or bisoprolol 2.5-5 mg daily) and titrate to effect, monitoring heart rate response. If beta blockers are contraindicated or poorly tolerated, ivabradine is an excellent alternative as it specifically targets heart rate without affecting blood pressure or bronchial tone.
Continue routine heart rate monitoring at each clinical encounter as part of comprehensive ADR screening, which should occur every 3 months after the first 2 years of treatment. 1